GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology

Glucotrack (GCTK) provided a recap of the critical operational milestones which have positioned the company to submit an IDE to the FDA for its continuous blood glucose monitoring technology, with a goal to file requisite documents with the FDA during Q2. “In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack’s foundation,” commented Paul Goode, president and CEO of Glucotrack. “The completion of our first-in-human study in Brazil and initiation of our follow up study in Australia enables us to advance toward our U.S. clinical program. With trial infrastructure in place and product enhancements completed, we are prepared to initiate the study, pending FDA approval.”